Randomised, double-blind, placebo-controlled multicenter study to assess management strategies in the treatment of Helicobacter pylori infected patients with gastro-oesophageal reflux disease (GERD)

Study identifier:D9612L00201

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Randomised, double-blind, placebo-controlled multicenter study to assess management strategies in the treatment of Helicobacter pylori infected patients with gastro-oesophageal reflux disease (GERD)

Medical condition

gastrointestinal diseases

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Nov 2003

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2084&filename=CSR-D9612L00201.pdf
Download
CSR-D9612L00201.pdf
Download
Trial Results Summaries
Available here

Randomised, double-blind, placebo-controlled multicenter study to assess management strategies in the treatment of Helicobacter pylori infected patients with gastro-oesophageal reflux disease (GERD)

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2084&filename=CSR-D9612L00201.pdf

CSR-D9612L00201.pdf

Trial Results Summaries